The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL HL Update 2021 | Response biomarkers in HL
Sven Borchmann, MD, University of Cologne, Cologne, Germany, discusses the genetics of classical Hodgkin lymphoma (HL) and the use of biomarkers as a response marker, as discussed at the virtual Update on Hodgkin Lymphoma organized by the International Symposium on Hodgkin Lymphoma (ISHL). Dr Borchmann highlights the potential of circulating tumor DNA and protein-based biomarkers that can be used alongside PET imaging to determine a patient’s response to treatment in clinical practice and trial settings. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
